Preserving Patient Access to Home Infusion Act Whack-a-Mole Bill
Are you familiar with the Preserving Patient Access to Home Infusion Act (PPAHIA)? You probably should be. It has been kicking around the halls of
July 20, 2023
Are you familiar with the Preserving Patient Access to Home Infusion Act (PPAHIA)? You probably should be. It has been kicking around the halls of
FDA has now approved four gene therapies within the past ninety days. That’s got to be a record! The FDA recently approved a new infused
Not all specialty pharmacies operate a compounding line of business….. but there are a number of SPs that do. If your pharmacy is into compounding, then you
Another sonic boom could be heard (well….. at least by dogs) recently when the FDA approved yet another gene therapy! This time the news was truly
The FDA recently approved a new infused therapy, Columvi (glofitamab-gxbm) from Genentech, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large
A boatload of biosimilars are now sitting in the approval circle since the first one was approved in early 2015. Copies of just four market
Lots of angst between the FEDA and Pharma over drug pricing controls and price negotiations. There will be lobbying a’plenty by Pharma to mitigate what is already
The FDA recently approved a new extended release oral-suspension therapy, Lumryz (sodium oxybate) from Avadel Pharmaceuticals, for the treatment of cataplexy or excessive daytime sleepiness
And the beat goes on…….. We’ve covered the market moves of both CVS and Walgreens as they transition from a pharmacy centric business model to
The excitement in the air is palpable…. Yes, another biosimilar to Humira has been approved by the FDA!! Hallelujah!! Ummm….. wait….. the degree of excitement may be….. exaggerated.
